| PAR Stock | | | 0.43 0.01 2.38% |
Founder
Grad BSc is MD Founder of Paradigm Biopharmaceuticals
| Age | 66 |
| Phone | 61 3 9629 5566 |
| Web | https://www.paradigmbiopharma.com |
Paradigm Biopharmaceutica Management Efficiency
The company has return on total asset
(ROA) of
(0.3314) % which means that it has lost $0.3314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.4291) %, meaning that it generated substantial loss on money invested by shareholders. Paradigm Biopharmaceutica's management efficiency ratios could be used to measure how well Paradigm Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
Paradigm Biopharmaceuticals (PAR) is traded on Australian Securities Exchange in Australia and employs 11 people.
Management Performance
Paradigm Biopharmaceutica Leadership Team
Elected by the shareholders, the Paradigm Biopharmaceutica's board of directors comprises two types of representatives: Paradigm Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paradigm. The board's role is to monitor Paradigm Biopharmaceutica's management team and ensure that shareholders' interests are well served. Paradigm Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paradigm Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Grad BSc, MD Founder | |
| Simon White, Director Relations | |
| MS MD, Chief Director | |
| Ravi Krishnan, Chief Officer | |
| Michael Imperiale, Global MPS | |
| Justin Cahill, Chief Officer | |
| Mukesh Ahuja, Global OA | |
| BCom BSc, Interim CFO | |
| Beverley Huttmann, Commercial Head | |
| Michelle Coffey, Global Affairs | |
| Marco Polizzi, Ex Officer | |
Paradigm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Paradigm Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Paradigm Stock Analysis
When running Paradigm Biopharmaceutica's price analysis, check to
measure Paradigm Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paradigm Biopharmaceutica is operating at the current time. Most of Paradigm Biopharmaceutica's value examination focuses on studying past and present price action to
predict the probability of Paradigm Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Paradigm Biopharmaceutica's price. Additionally, you may evaluate how the addition of Paradigm Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.